Condition: Relapsed or Refractory Multiple Myeloma (RRMM) · Sponsor: Chongqing Precision Biotech Co., Ltd
This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the treatment of relapsed or refractory multiple myeloma.
This description comes directly from the study's public registry record.
Sanbin Wang, PhD · +86 13187424131 · sanbin1011@163.com
Always discuss trial participation with your own doctor first.
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07715630